Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $1.29 Million - $1.92 Million
-3,800 Reduced 77.55%
1,100 $418,000
Q3 2023

Nov 15, 2023

BUY
$369.35 - $548.43 $1.81 Million - $2.69 Million
4,900 New
4,900 $2.41 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $35.3B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.